Is Point-of-Care Hepatitis C Virus Testing Too Expensive?
-
January 14, 2026
-
2 min
Clinical Report: Is Point-of-Care Hepatitis C Virus Testing Too Expensive?
Overview
Point-of-care RNA testing for hepatitis C virus could significantly increase hospital laboratory costs, with potential annual increases of $2.9 million for a three-hospital system. Despite the benefits of immediate treatment initiation, the financial implications pose challenges for healthcare systems.
Background
Hepatitis C virus (HCV) remains a major public health concern, with effective screening and treatment strategies essential for achieving elimination goals. The integration of point-of-care testing could enhance immediate treatment opportunities, but cost-effectiveness remains a critical issue. Understanding the financial impact of these testing strategies is vital for healthcare systems aiming to improve HCV management.
Data Highlights
| Testing Strategy | Annual Cost Increase | Cost per Infection Detected |
|---|---|---|
| Point-of-Care RNA Testing | $2.9 million | $6,439 |
| County Hospital Emergency Department | $246,143 | 22% increase |
| Antibody Positivity Rate (ED) | 10.3% | |
| Antibody Positivity Rate (Outpatient Clinics) | 2.7% | |
| Median Turnaround Time (Traditional Testing) | 84 hours | |
| Median Turnaround Time (New Platforms) | 45 hours | |
| Cost of Antigen Testing | $11,494 |
Key Findings
- Point-of-care RNA testing could increase laboratory costs by up to 260%.
- Annual costs for implementing point-of-care RNA testing in a three-hospital system could reach $2.9 million.
- Emergency department testing for HCV increased by 682% from 2017 to 2024.
- The antibody positivity rate in the county hospital emergency department is 10.3%, compared to 2.7% in outpatient clinics.
- HCV antigen testing may be a cost-effective alternative, adding only $11,494 in annual costs.
- Current Medicare reimbursement rates do not reflect the actual costs of point-of-care RNA testing.
Clinical Implications
Suggest specific alternative strategies or examples of antigen testing to enhance completeness.
Conclusion
The financial burden of point-of-care RNA testing for hepatitis C virus poses significant challenges for healthcare systems. Strategic deployment and funding mechanisms are essential to support HCV elimination efforts without compromising other laboratory services.
Related Resources & Content
- University of Washington, Journal of Clinical Microbiology, 2023 -- Is Point-of-Care Hepatitis C Virus Testing Too Expensive?
- The Journal of Infectious Diseases, 2023 -- Rapid Hepatitis C Virus RNA Testing at the Point of Care Achieves 15-Minute Results
- Open Forum Infectious Diseases, 2023 -- Economic Evaluation of Various Hepatitis C Diagnosis and Treatment Strategies for Treatment-Naive Individuals Who Inject Drugs in Australia
- The Journal of Infectious Diseases, 2023 -- Creation of a Quick Automated Point-of-Care Test for Hepatitis C Viral RNA Utilizing the DASH Rapid PCR System
- CDC, Clinical Screening and Diagnosis for Hepatitis C, 2025 -- Current Guidance on HCV Testing
- The New Gastroenterologist — Unfulfilled Potential of a Promising Hepatitis C Treatment
- CDC Guidance on Hepatitis C Testing
- Optimizing Hepatitis C Virus Testing
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
